GI Dynamics Release: Data from Clinical Trial of EndoBarrier(TM) Gastrointestinal Liner in Patients with Type 2 Diabetes to be Presented at the First World Congress on Interventional Therapies for Type 2 Diabetes in New York City

LEXINGTON, Mass.--(BUSINESS WIRE)--GI Dynamics, a medical device company pioneering the development of new approaches to treating metabolic disorders, today announced that new data regarding EndoBarrier™, its novel, noninvasive device currently in clinical trials to treat obesity and type 2 diabetes, will be presented at the First World Congress on Interventional Therapies for Type 2 Diabetes in New York City.

MORE ON THIS TOPIC